Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 1125-1131

  Valmori, Danila ^a   Lévy, Frederic ^b   Miconnet, Isabelle ^b   Zajac, Paul ^c   Spagnoli, Giulio C ^c   Rimoldi, Donata ^b   Liénard, Danielle ^a   Cerundolo, Vincenzo ^d   Cerottini, Jean Charles ^a   Romero, Pedro ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; MELANOMA ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 17544403916     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.1125     Document Type: Article

References (44)

1. Romero, P. 1996. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin. Immunopathol. 18:185.
2. Robbins, P. F., and Y. Kawakami. 1996. Human tumor antigens recognized hy T cells. Curr. Opin. Immunol. 8:628.
3. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
4. Falo, L. D., Jr., L. J. Colarusso, B. Benacerraf, and K. L. Rock. 1992. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc. Natl. Acad. Sci. USA 89:8347.
5. Maryanski, J., P. Romero, and G. Corradin. 1991. Differential stability of antigenic MHC class I-restricted synthetic peptides. J. Immunol. 147:1745.
6. Ayyoub, M., B. Monsarrat, H. Mazarguil, and J. E. Gairin. 1998. Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogs. Rapid Commun. Mass Spectrom. 12:557.
7. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3:37.
8. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
9. Toes, R. E. M., R. Offringa, R. J. J. Blom, C. J. M. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
10. Zhai, Y., J. C. Yang, P. Spiess, M. I. Nishimura, W. W. Overwijk, B. Roberts, N. P. Restifo, and S. A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART-1 and gp100. J. Immunother. 20:15.
11. Zhai, Y. F., J. C. Yang, Y. Kawakami, P. Spiess, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, and S. A. Rosenberg. 1996. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J. Immunol. 156:700.
12. Wang, M., V. Bronte, P. Chen, L. Gritz, D. Panicali, S. A. Rosenberg, and N. P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
13. Irvine, K. R., R. S. Chamberlain, E. P. Shulman, D. R. Surman, S. A. Rosenberg, and N. P. Restifo. 1997. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 86:1595.
14. Zajac, P., D. Oertli, G. C. Spagnoli, C. Noppen, C. Schaefer, M. Heberer, and W. R. Marti. 1997. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding Mart-1/Melan-A 27-35 epitope. Int. J. Cancer 71:491.
15. Kim, C. J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Dendritic cells infected with pox-viruses encoding MART-1/melan A sensitize T lymphocytes in vitro. J. Immunother. 20:276.
16. Rosenberg, S. A., Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1894.
17. Naftzger, C., Y. Takechi, H. Kohda, I, Hara, S. Vijayasaradhi, and A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809.
18. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robhins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma anligen gp100 modified HLA-A*0201-binding residues. J. Immunol. 157:2539.
19. Valmori, D., J. F. Fonteneau, C. Marañón Lizana, N. Gervois, D. Liénard, D. Rimoldi, C. V. Jongeneel, F. Jotereau, J.-C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs. J. Immunol. 160:1750.
20. Valmori, D., N. Gervois, D. Rimoldi, J. F. Fonteneau, A. Bonelo, D. Liénard, L. Rivoltini, F. Jotereau, J.-C. Cerottini, and P. Romero. 1998. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 161:6956.
21. Valmori, D., M. J. Pittet, D. Rimoldi, D. Liénard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Ceroltini, and P. Romero. 1999. An antigen targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59:2167.
22. Men, Y., I. Miconnet, D. Valmori, D. Rimoldi, J.-C. Cerottini, and P. Romero. 1999. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0202/Kb transgenic mice. J. Immunol. 162:3566.
23. Tsung, K., J. H. Yim, W. Marti, R. M. Buller, and J. A. Norton. 1996. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol. 70:165.
24. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J.-C. Cerottini, P. Romero, V. Cerundolo, and F. Lévy. 1999. Modulation of proteasomal activity required for the generation of a CTL-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:895.
25. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Liénard, J.-C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J. Exp. Med. 188:1641.
26. Elsasser-Beile, U., S. von Kleist, and H. Gallati. 1991. Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J. Immunol. Methods 139:191.
27. Lévy, F., N. Johnsson, T. Rumenapf, and A. Varshavsky. 1996. Using ubiquitin to follow the metabolic fate of a protein. Proc. Natl. Acad. Sci. USA 93:4907.
28. Wilkinson, K. D., and M. Hochstrasser. 1998. Ubiquitin and the Biology of the Cell. Plenum Press, New York, p. 99.
29. Bettinotti, M. P., C. J. Kim, K. H. Lee, M. Roden, J. N. Cormier, M. Panelli, K. K. Parker, and F. M. Marincola. 1998. Stringent allele/epitope requirements for MART-1/melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol. 161:877.
30. Nossal, G. J. V. 1994. Negative selection of lymphocytes. Cell 76:229.
31. von Boehmer, H. 1994. Positive selection of lymphocytes. Cell 76:219.
32. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, et al. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
33. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastalic melanoma. Nat. Med. 4:321.
34. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognised by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
35. Romero, P., N. Gervois, J. Schneider, P. Escohar, D. Valmori, C. Pannetier, A. Sleinle, T. Wölfel, D. Liénard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
36. + T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res. 58:2433.
37. Kawakami, Y., J. K. Battles, T. Kobayashi, W. Ennis, X. Wang, J. P. Tupesis, F. M. Marincola, P. F. Robbins, V. J. Hearing, M. A. Gonda, et al. 1997. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J. Immunol. Methods 202:13.
38. Goldberg, A. L., and K. L. Rock. 1992. Proteolysis, proteasomes and antigen presentation. Nature 357:375.
39. Monaco, J. J. 1995. Pathways for the processing and presentation of antigens to T cells. J. Leukocyte Biol. 57:543.
40. Elliott, T., A. Willis, V. Cerundolo, and A. Townsend. 1995. Processing of major histocompatibility class I-restricled antigens in the endoplasmic reticulum. J. Exp. Med. 181:1481.
41. Snyder, H. K., J. W. Yewdell, and J. R. Bennink. 1994. Trimming of antigenic peptides in an early secretory compartment. J. Exp. Med. 180:2389.
42. Van Binnendijk, R. S., C. A. van Baalen, M. C. M. Poelen, P. De Vries, J. Boes, V. Cerundolo, A. D. M. E. Osterhaus, and F. G. C. M. Uytdehaag. 1992. Measles virus transmembrane fusion protein synthesized De Novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176:119.
43. + CTL. J. Immunol. 154:6140.
44. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, Jr., C. L. Slingluff, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1998. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37.